Source:http://linkedlifedata.com/resource/pubmed/id/11578907
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2001-10-1
|
pubmed:abstractText |
The syntheses, radiolabeling, antibody conjugation, and in vivo evaluation of new linkers for 211At labeling of humanized anti-Tac (Hu-anti-Tac), an antibody to the alpha-chain of the IL-2 receptor (IL-2Ralpha) shown to be a useful target for radioimmunotherapy are described. Synthesis of the organometallic linker precursors is accomplished by reaction of the corresponding bromo- or iodoaryl esters with bis(tributyltin) in the presence of a palladium catalyst. Subsequent conversion to the corresponding N-succinimidyl ester and labeling with 211At of two new linkers, N-succinimidyl 4-[211At]astato-3-methylbenzoate and N-succinimidyl N-(4-[211At]astatophenethyl)succinamate (SAPS), together with the previously reported N-succinimidyl 4-[211At]astatobenzoate and N-succinimidyl 3-[211At]astato-4-methylbenzoate, are each conjugated to Hu-anti-Tac. The plasma survival times of these conjugates are compared to those of directly iodinated (125I) Hu-anti-Tac. The N-succinimidyl N-(4-[211At]astatophenethyl)succinamate compound (SAPS) emerged from this assay as the most viable candidate for 211At-labeling of Hu-anti-Tac. SAPS, along with the directly analogous radio-iodinated reagent, N-succinimidyl N-(4-[125I]astatophenethyl)succinamate (SIPS), are evaluated in a biodistribution study along with directly iodinated (125I) Hu-anti-Tac. Blood clearance and biological accretion results indicate that SAPS is a viable candidate for further evaluation for radioimmunotherapy of cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Astatine,
http://linkedlifedata.com/resource/pubmed/chemical/Indicators and Reagents,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Succinimides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0969-8051
|
pubmed:author |
pubmed-author:BeitzelM PMP,
pubmed-author:BrechbielM WMW,
pubmed-author:EckelmanW CWC,
pubmed-author:GansowO AOA,
pubmed-author:GarmestaniKK,
pubmed-author:HerringBB,
pubmed-author:HoranHH,
pubmed-author:PhillipsK EKE,
pubmed-author:PlascjakP SPS,
pubmed-author:SchwarzU PUP,
pubmed-author:WaldmannT ATA,
pubmed-author:YauPP,
pubmed-author:YordanovA TAT,
pubmed-author:ZhangMM,
pubmed-author:ZhangZZ
|
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
845-56
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11578907-Animals,
pubmed-meshheading:11578907-Antibodies,
pubmed-meshheading:11578907-Astatine,
pubmed-meshheading:11578907-Chromatography, High Pressure Liquid,
pubmed-meshheading:11578907-Female,
pubmed-meshheading:11578907-Indicators and Reagents,
pubmed-meshheading:11578907-Isotope Labeling,
pubmed-meshheading:11578907-Magnetic Resonance Spectroscopy,
pubmed-meshheading:11578907-Mice,
pubmed-meshheading:11578907-Mice, Nude,
pubmed-meshheading:11578907-Radiopharmaceuticals,
pubmed-meshheading:11578907-Receptors, Interleukin-2,
pubmed-meshheading:11578907-Succinimides,
pubmed-meshheading:11578907-Tissue Distribution
|
pubmed:year |
2001
|
pubmed:articleTitle |
Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
|
pubmed:affiliation |
Radiation Oncology Branch, Division of Clinical Sciences, National Cancer Institute, Department of Nuclear Medicine, Bethesda, MD 20892, USA.
|
pubmed:publicationType |
Journal Article
|